类风湿关节炎中阿达木单抗与英夫利西单抗抗药抗体发生率及危险因素
该研究基于ABIRISK项目的欧洲回顾性队列,纳入366例接受阿达木单抗(n=240)或英夫利西单抗(n=126)治疗的类风湿关节炎患者,其中92.4%为未用过抗TNF药物者、96.6%合用甲氨蝶呤,随访至18个月。结果显示18个月内抗药抗体(ADA)检出率分别为19.2%和29.4%,且随时间持续升高;病程、DAS28和终生吸烟是ADA发生的临床预测因素。
要点
- 18个月内阿达木单抗组ADA检出率19.2%、英夫利西单抗组29.4%,且随时间持续上升
- 病程1–3年较<1年ADA风险升高:阿达木单抗HR 3.0、英夫利西单抗HR 2.7
- DAS28 3.2–5.1与英夫利西单抗组终生吸烟亦与ADA风险升高相关
核心结论
- 在多数合用甲氨蝶呤的类风湿关节炎患者中,阿达木单抗和英夫利西单抗的ADA可较晚出现,且风险在18个月内持续增加。
- 病程较长、DAS28中度活动和终生吸烟是ADA发生的临床预测因素。
研究设计与样本
- 欧洲ABIRISK项目回顾性队列合并分析,共366例类风湿关节炎患者,阿达木单抗n=240、英夫利西单抗n=126。
- 92.4%为未用过抗TNF药物者(328/355),96.6%合用甲氨蝶呤(341/353),随访至18个月,ADA以酶联免疫吸附试验检测,采用区间删失数据Cox回归分析。
主要发现
- 18个月内ADA检出率:阿达木单抗组19.2%(n=46),英夫利西单抗组29.4%(n=37)。
- ADA累积发生率随时间上升,3、6、12、15、18个月时阿达木单抗组分别为15.4%(5.2-20.2)、17.6%(11.4-26.4)、17.7%(12.6-37.5)、50.0%(25.9-87.5)、50.0%(25.9-87.5)。
- 同时点英夫利西单抗组分别为0%(0-5.9)、0%(0-25.9)、34.1%(11.4-46.3)、37.5%(25.9-77.4)、66.7%(37.7-100)。
关键数值与推荐
- 病程1–3年对比<1年:阿达木单抗HR 3.0(95% CI 1.0-8.7),英夫利西单抗HR 2.7(95% CI 1.1-6.8)。
- DAS28 3.2–5.1对比<3.2:阿达木单抗HR 6.6(95% CI 1.3-33.7)。
- 终生吸烟:英夫利西单抗HR 2.7(95% CI 1.2-6.3)。
临床怎么用
- 对接受阿达木单抗或英夫利西单抗的类风湿关节炎患者,应关注18个月内ADA的晚期出现并持续监测。
- 可将病程较长、DAS28中度活动及终生吸烟作为ADA风险较高的提示因素。
局限性
- 为回顾性队列合并分析,ADA数据依赖酶联免疫吸附试验检测。
- 原文摘要未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the incidence of anti-drug antibody (ADA) occurrences and ADA-related risk factors under adalimumab and infliximab treatment in rheumatoid arthritis (RA) patients. METHODS: The study combined retrospective cohorts from the ABIRISK project totaling 366 RA patients treated with adalimumab (n = 240) or infliximab (n = 126), 92.4% of them anti-TNF naive (n = 328/355) and 96.6% of them co-treated with methotrexate (n = 341/353) with up to 18 months follow-up. ADA positivity was measured by enzyme-linked immunosorbent assay. The cumulative incidence of ADA was estimated, and potential bio-clinical factors were investigated using a Cox regression model on interval-censored data. RESULTS: ADAs were detected within 18 months in 19.2% (n = 46) of the adalimumab-treated patients and 29.4% (n = 37) of the infliximab-treated patients. The cumulative incidence of ADA increased over time. In the adalimumab and infliximab groups, respectively, the incidence was 15.4% (5.2-20.2) and 0% (0-5.9) at 3 months, 17.6% (11.4-26.4) and 0% (0-25.9) at 6 months, 17.7% (12.6-37.5) and 34.1% (11.4-46.3) at 12 months, 50.0% (25.9-87.5) and 37.5% (25.9-77.4) at 15 months and 50.0% (25.9-87.5) and 66.7% (37.7-100) at 18 months. Factors associated with a higher risk of ADA development were: longer disease duration (1-3 vs. < 1 year; adalimumab: HR 3.0, 95% CI 1.0-8.7; infliximab: HR 2.7, 95% CI 1.1-6.8), moderate disease activity (DAS28 3.2-5.1 vs. < 3.2; adalimumab: HR 6.6, 95% CI 1.3-33.7) and lifetime smoking (infliximab: HR 2.7, 95% CI 1.2-6.3). CONCLUSIONS: The current study focusing on patients co-treated with methotrexate for more than 95% of them found a late occurrence of ADAs not previously observed, whereby the risk continued to increase over 18 months. Disease duration, DAS28 and lifetime smoking are clinical predictors of ADA development.
引用
- Quistrebert J, Hässler S, Bachelet D, et al. Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. Semin Arthritis Rheum. 2018. PMID: 30420245. doi:10.1016/j.semarthrit.2018.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。